Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Baek‐Yeol Ryoo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9052-833X; OpenAlex author ID A5050625196. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 0, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2016: 1 trial · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 29

  1. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  2. Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning. Co-author DOI 10.1200/cci-25-00124↗
  3. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  4. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  5. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  6. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  7. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  8. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  9. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  10. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism i… Co-author DOI 10.3390/cancers14030559↗
  11. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  12. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  13. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  14. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventiona… Co-author DOI 10.1177/17588359211003053↗
  15. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Last author DOI 10.1200/jco.20.02232↗
  16. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  17. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcin… Co-author DOI 10.1177/1758835920923424↗
  18. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Last author DOI 10.1177/1758835920953294↗
  19. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  20. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  21. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.4143/crt.2019.190↗
  22. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammat… Last author DOI 10.1007/s10637-018-0681-y↗
  23. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Last author DOI 10.1177/1758835919871126↗
  24. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  25. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Last author DOI 10.1007/s10637-017-0497-1↗
  26. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Last author DOI 10.1007/s10637-018-0598-5↗
  27. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  28. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  29. Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Co-author DOI 10.21873/anticanres.11374↗

Trials 1

  1. Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer Principal investigator NCT02749136↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu‐pyo Kim · 27 shared papers, 2017–2026 · strength 3.28
  2. Changhoon Yoo · 26 shared papers, 2017–2026 · strength 3.23
  3. Song Cheol Kim · 18 shared papers, 2017–2026 · strength 2.08
  4. Dae Wook Hwang · 17 shared papers, 2017–2026 · strength 1.95
  5. Ki Byung Song · 16 shared papers, 2017–2026 · strength 1.87
  6. Tae Jun Song · 14 shared papers, 2017–2026 · strength 1.65
  7. Do Hyun Park · 13 shared papers, 2017–2024 · strength 1.40
  8. Jin‐hong Park · 12 shared papers, 2017–2026 · strength 1.32
  9. Woohyung Lee · 9 shared papers, 2020–2026 · strength 1.24
  10. Sang Soo Lee · 12 shared papers, 2017–2024 · strength 1.14
  11. Dongwook Oh · 7 shared papers, 2020–2026 · strength 1.07
  12. Yejong Park · 6 shared papers, 2020–2024 · strength 0.87
  13. Dong Wan Seo · 9 shared papers, 2017–2024 · strength 0.85
  14. Bong Jun Kwak · 5 shared papers, 2022–2024 · strength 0.78
  15. Inkeun Park · 4 shared papers, 2024–2026 · strength 0.76
  16. Hyehyun Jeong · 4 shared papers, 2020–2026 · strength 0.70
  17. Myung‐Hwan Kim · 8 shared papers, 2017–2022 · strength 0.64
  18. Seung‐Mo Hong · 5 shared papers, 2017–2024 · strength 0.51
  19. Seung Soo Lee · 3 shared papers, 2020–2026 · strength 0.47
  20. Eunsung Jun · 3 shared papers, 2020–2024 · strength 0.37
  21. Min Kyu Sung · 2 shared papers, 2024 · strength 0.36
  22. Inhwan Hwang · 4 shared papers, 2018–2020 · strength 0.35
  23. Hyunseok Yoon · 2 shared papers, 2023–2024 · strength 0.32
  24. Zev A. Wainberg · 2 shared papers, 2020–2024 · strength 0.29
  25. Hye Jin Choi · 2 shared papers, 2019–2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.